ArticleNucleic acids research2025
An engineered CRISPR-Cas12i tool for efficient multiplexed genome editing.
Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Synergistic engineering of Casδ nuclease for robust genome editing.Journal of integrative plant biology · 2026Article
- CasY7: An optimized Cas12i system for enhanced genome editing in monocot crops.Journal of integrative plant biology · 2026Article
- Improving growth performance across multiple sheep breeds by targeting the MSTN gene using an enhanced Cas12i system.Science China. Life sciences · 2026Article
- Current and Emerging Therapeutic Strategies for the Treatment of Duchenne Muscular Dystrophy.Genes · 2026Review
- Improved efficiency of genetic transformation for the development of elite germplasm using CRISPR/Cas12i3 in maize.aBIOTECH · 2026Article
- Production of gene-edited cloned cattle embryos using the CRISPR/EOCas12i system.Frontiers in genome editing · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Developing efficient and simplified tools for multiplexed genome editing remains challenging due to limitations in precursor CRISPR RNA (pre-crRNA) processing and reliance on additional RNA-based regulatory components. Cas12i.3, a small RNA-guided nuclease, reportedly lacks pre-crRNA processing ability, restricting its multiplexing capability. Here, we engineered Cas12i.3 by optimizing CRISPR RNA (crRNA) design, codon usage, and exonuclease fusion, generating initial optimized Cas12i (IOCas12i) system. Further rational design and amino acid mutations yielded the highly efficient enhanced optimized Cas12i (EOCas12i) systems, EOCas12i-Combo1 and EOCas12i-Combo2, exhibiting 2.5- to 22.8-fold and 3.0- to 60.0-fold editing efficiencies relative to wild-type Cas12i.3, comparable to Streptococcus pyogenes Cas9 (SpCas9) and Lachnospiraceae bacterium Cas12a (LbCas12a). Additionally, they exhibited high specificity and produced longer insertions and deletions (indels) that may facilitate gene knockout. Notably, both variants enabled efficient multiplexed editing of up to 30 targets using compact crRNA arrays. These advancements position EOCas12i-Combo1 and EOCas12i-Combo2 as promising platforms for multiplexed genome editing applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.